Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Specialist Applauds Lilly’s Kisunla for Offering Treatment Goal
October 30, 2024
- Expert Hails Japan Approval of Gilead’s Trodelvy for Triple-Negative Breast Cancer
October 30, 2024
- Meiji Pharma to Discontinue Sales of Abilify Generics
October 30, 2024
- Astellas Recalls Some Batches of Betanis over Nitrosamine Impurities
October 30, 2024
- Sandoz Gives Update on Anapeine Supply after Manufacturing Change
October 30, 2024
- Xocova Makes Mark in PIII Study for Post-Exposure Prophylaxis: Shionogi
October 30, 2024
- Amitiza Tops Drug Promotion Rankings for 5 Channels in September: Intage
October 30, 2024
- Shionogi Set to Make “QOL Diseases” Next Leg of Business: CEO
October 29, 2024
- Shionogi’s H1 Sales Dip on One-Off Factor, HIV Franchise Grows
October 29, 2024
- Astellas Pulls EU Filing for Geographic Atrophy Drug
October 29, 2024
- Astellas Drastically Shaving Research Time with AI Drug Discovery
October 28, 2024
- AbbVie Taps Tiago Campos Rodrigues as Japan President
October 28, 2024
- Chugai Net Profit Jumps to Nearly 300 Billion Yen on Brisk Exports
October 28, 2024
- Recordati to Enter Japan’s Hematology/Oncology Market with Enjaymo Acquisition
October 25, 2024
- Novo Inks Collab Pact with Kasugai City on Obesity Measures
October 25, 2024
- Shionogi-Ube’s Anti-RSV Drug Gets Fast-Track Tag in US
October 25, 2024
- Misako Hamamura to Head Up Alexion Japan from Next Year
October 25, 2024
- Guardant to Close Japan Lab Due to Sluggish Product Uptake
October 24, 2024
- NHI-Market Price Gap Expected to Contract in 2024, Will It Enter Lower 5% Territory?
October 24, 2024
- Otsuka’s IgA Nephropathy Drug Makes Mark in PIII, Eyes Accelerated Path
October 23, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…